Amalgamated Bank Sells 8,028 Shares of Bruker Co. (NASDAQ:BRKR)

Amalgamated Bank lowered its position in Bruker Co. (NASDAQ:BRKR) by 10.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 65,833 shares of the medical research company’s stock after selling 8,028 shares during the quarter. Amalgamated Bank’s holdings in Bruker were worth $4,837,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Lindbrook Capital LLC lifted its position in Bruker by 68.2% during the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 146 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Bruker during the 4th quarter worth $33,000. VisionPoint Advisory Group LLC grew its position in Bruker by 145.0% in the third quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock worth $32,000 after acquiring an additional 303 shares in the last quarter. Fifth Third Bancorp raised its position in Bruker by 53.3% during the third quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 188 shares in the last quarter. Finally, Life Planning Partners Inc bought a new stake in Bruker during the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

BRKR stock opened at $74.33 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. The firm has a 50 day moving average price of $86.98 and a 200-day moving average price of $75.44. Bruker Co. has a 52-week low of $53.79 and a 52-week high of $94.86. The firm has a market capitalization of $10.80 billion, a price-to-earnings ratio of 27.03, a PEG ratio of 1.73 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business had revenue of $721.70 million for the quarter, compared to the consensus estimate of $729.88 million. During the same period in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts forecast that Bruker Co. will post 2.82 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, February 29th. Bruker’s dividend payout ratio (DPR) is currently 7.27%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Stifel Nicolaus increased their price objective on Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group lifted their price target on shares of Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a research note on Wednesday, April 10th. Citigroup upped their price objective on shares of Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. JPMorgan Chase & Co. upgraded shares of Bruker from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $60.00 to $90.00 in a research report on Wednesday, February 14th. Finally, UBS Group upped their price target on shares of Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a research report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and an average price target of $84.86.

Insider Buying and Selling

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the sale, the director now directly owns 23,147 shares in the company, valued at approximately $2,084,618.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.30% of the stock is owned by company insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.